Update on a DNA-medicine biotech advancing a BLA review for an RRP therapy while reporting corporate progress and partner trial results.
Key Takeaways
- Announced its financial results for the second quarter ended June 30
- "We are confident in INO-3107's potential to become the preferred product among patients
- Regulatory progress includes completion of the late-cycle review meeting and all scheduled pre-licensure inspections